Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Takeover rumours: BioNTech, Cardiol Therapeutics and Novo Nordisk in focus

The biotech sector has significantly lagged behind the performance of artificial intelligence and high-tech this year. This is because of high inflation, which in turn has made an imminent interest rate cut unlikely. Nevertheless, Germany’s economic condit...

BASF and Cardiol Therapeutics recommended buys; TUI rides momentum

BASF (OTCQX:BASFY) shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the stock did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see ...

Take a closer look at HelloFresh, Bayer and Altech Advanced Materials

Bayer shares gained around 7 per cent last week. Is this the turnaround after the stock reached a multi-year low? Altech Advanced Materials stock is also working on an upward trend. The German battery hopeful has published a promising feasibility study. Their stationary s...

Can NervGen keep a lid on explosive news?

Speculation of early “evidence” of successful proof-of-concept human trials sparks stock rallies Trial volunteers taking a placebo are offered the real deal in a follow-up trial as a “reward” The company&Clo...

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...

Buzz on the Bullboards: Good stocks with bad publicity

It was hedge fund legend Ray Dalio who said: “He who lives by the crystal ball will eat shattered glass.” Many stock markets may have seen a higher start to the year so far, but there is far from a universal sentiment across the sectors, with s...

Pharmaceutical company treats bladder cancer with new tech

The following is a transcription of the above video, and The Market Herald Canada has edited it for clarity . Theralase Technologies Inc. (TSXV:TLT) , a clinical-stage pharmaceutical company, is currently developing an innovative, research-backed technology for the ...

Clinical research and tools to address mental health

Our next company is Numinus Wellness Inc. (TSX:NUMI) . Numinus is using the power of psychedelic medicine to make great strides in addressing serious mental health issues. It recently announced its fiscal year 2024 results, which showed strong growth in its busines...

Xcyte Digital goes public with one-stop immersive event technology

Xcyte Digital Corp. (TSXV:XCYT) has accrued more than 150,000 events with more than 100 million participants through its acquired business assets. The company provides immersive technology solutions – which include virtual, augmented and extended reality for compan...

Buzz on the Bullboards: More tricks than treats in today’s stock market?

It has been an uneasy week for markets on Bay Street and Wall Street. After the TSX hit a two-week low a few days ago, the Bank of Canada voted to keep interest rates at 5 per cent, kicking off a risk rally. U.S. markets have also fared well as optimism grows that...
1 2 3 4 5 6 7 8 9 10 ...